Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.

Andrew ÖstörFilip E Van den BoschKim PappCecilia AsnalRicardo Blanco-AlonsoJacob AelionGabriela AlperovichWenjing LuZailong WangAhmed M SolimanAnn EldredLisa BarcombAlan Kivitz

Published in: Annals of the rheumatic diseases (2021)

NCT03671148.

Keyphrases

placebo controlled
double blind
phase iii
phase ii
study protocol
clinical trial
open label
randomized controlled trial